Su­per­nus touts win­ning da­ta in adult AD­HD as it looks to make its case with the FDA — again — for pe­di­atric use

Less than two months af­ter be­ing re­ject­ed by the FDA for pe­di­atric pa­tients, Su­per­nus Phar­ma­ceu­ti­cals’ AD­HD pro­gram has new da­ta in an old­er pop­u­la­tion that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER